# McKesson

Type: Company (MCK)

Source: GetYourBrief — https://getyourbrief.com/entity/mckesson
Canonical HTML page: https://getyourbrief.com/entity/mckesson

## Recent coverage (4 stories, network-wide)

### 27 of 287 Applicants Win $12M in Colorado Opioid Prevention Grants
2026-08-02 19:24:44 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 1

Colorado’s $12M opioid grant round, awarded to 27 organizations, will bolster youth treatment, prison re-entry support, and a rural behavioral health workforce—key gaps in the state’s healthcare delivery system. The highly competitive process drew 287 applications, highlighting the severe need for prevention infrastructure.
Full story: https://gethealthbrief.com/story/colorado-opioid-settlement-grants-healthcare-workforce

### Colorado’s $12M Opioid Grant Signals Ongoing Settlement Costs for Pharma
2026-08-02 19:24:34 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 1

Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Full story: https://getbiobrief.com/story/colorado-opioid-settlement-pharma-liability-costs

### NovoCure’s $655M Revenue Signals a Shift in Direct-to-Patient Cancer Care
2026-06-28 04:07:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
Full story: https://gethealthbrief.com/story/novocure-direct-patient-model-healthcare-2026

### Amgen’s $36.8B Pipeline vs NovoCure’s Tumor-Fighting Tech: Which Innovator Wins?
2026-06-28 04:07:18 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amgen brings a massive $36.8B revenue base and a broad chronic disease pipeline, while NovoCure pushes the frontier with electric‑field cancer therapy. This analysis weighs drug development scale against device‑based oncology innovation for biotech investors.
Full story: https://getbiobrief.com/story/amgen-vs-novocure-biopharma-innovation-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.